🧾 What This Document Is

This is a 6-K form, which is a current report that foreign companies listed on U.S. exchanges must file with the SEC to announce major news. In this case, the "news" is official notification from the Nasdaq stock exchange that Evogene's stock price is too low.

👉 Why it matters: This isn't an earnings report. It's a regulatory alert about the company's listing status. It's a "yellow flag" that triggers a formal process to avoid being removed from the exchange.

🏢 What The Company Does

Evogene Ltd. is an Israeli company that uses artificial intelligence (AI) and computational chemistry to design new small molecules. They focus on two main areas: creating new drugs (pharmaceuticals) and developing new agricultural products like pesticides or plant enhancements (agriculture).

👉 In simple terms: Imagine having a supercomputer that can explore millions of chemical possibilities to invent new, useful molecules for medicine and farming. That's what Evogene aims to do with its technology called ChemPass AI™.

📩 The Nasdaq "Compliance Alert"

Evogene received a formal letter from Nasdaq because its stock has been trading below the $1.00 minimum closing price for 30 consecutive business days.

👉 Why it matters: Nasdaq has rules to ensure listed companies maintain a certain minimum stock price. Falling below this rule doesn't mean immediate delisting, but it starts a clock ticking.

⏳ The Compliance Clock & Options

Evogene now has a 180-day "cure period," until September 28, 2026, to fix the problem.

• How to fix it: The stock price must close at or above $1.00 for at least 10 consecutive business days within this period.
• What if they fail? If they don't regain compliance by September 28, they could get an additional 180 days if they meet other listing requirements.
• The nuclear option: If all else fails, the company stated it could consider a reverse stock split. This action reduces the number of shares, which proportionally increases the stock price (e.g., a 1-for-10 split turns 10 shares worth $0.50 each into 1 share worth $5.00).

📉 What This Signals

This notification signals that the market has significantly devalued Evogene's shares, pushing them into "penny stock" territory (below $1). While it's a procedural step, it highlights investor skepticism or challenges in the company's business execution or market conditions.

👉 The company's priority: Evogene explicitly states that "continued listing on Nasdaq remains a key priority." Being delisted would reduce visibility, liquidity, and access to many institutional investors.

⚖️ Big Picture

• 👍 Strengths in the situation: The process has clear rules and a long timeline. The company is aware, proactive, and has stated its intention to find a solution. The Tel Aviv Stock Exchange listing is unaffected.
• ⚠️ Risks & Concerns: The low stock price reflects weak market confidence. A reverse stock split is often seen as a sign of desperation and can lead to further share price decline afterward. If they fail to regain compliance, delisting would be a major negative event.

🌍 Industry Context

Biotechnology and agri-tech companies like Evogene are often pre-revenue or in long, expensive R&D cycles. Their stock prices can be highly volatile and sensitive to scientific results, funding news, and broader market sentiment toward speculative tech. Trading below $1 is not uncommon in this sector during tough periods.

🧠 The Analogy

Think of it like a student on academic probation. The teacher (Nasdaq) says your grades (stock price) are too low. You have one semester (180 days) to bring them up. If you fail, you might get a conditional second chance, but eventually, you could be asked to leave the school (delist). A "reverse split" is like combining several of your weak grades into one stronger-looking grade—it doesn't change what you've learned, but it changes how it looks on the report card.

📇 Key Contacts & People

• Investor Relations Contact: Email: [email protected] Tel: +972-8-9311901
• (No individual names of executives or directors were provided in this filing).

🧩 Final Takeaway

Evogene is now on a 180-day countdown until September 28, 2026, to get its stock price back above $1 or risk being delisted from Nasdaq. The company says it will explore all options, including a reverse stock split, to stay listed. This is a serious warning sign about market confidence that the company must actively manage.